MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 3.4% – Time to Sell?

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA)’s stock price dropped 3.4% during trading on Thursday . The company traded as low as $2.36 and last traded at $2.57. Approximately 120,695 shares changed hands during trading, a decline of 59% from the average daily volume of 292,118 shares. The stock had previously closed at $2.66.

MAIA Biotechnology Stock Performance

The stock has a market cap of $61.45 million, a price-to-earnings ratio of -1.58 and a beta of 0.31.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Friday, August 9th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.16. On average, equities analysts anticipate that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Institutional Trading of MAIA Biotechnology

Institutional investors have recently made changes to their positions in the stock. Mather Group LLC. lifted its holdings in shares of MAIA Biotechnology by 50,150.0% during the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after buying an additional 12,036 shares during the period. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology during the second quarter valued at $56,000. Finally, Virtu Financial LLC purchased a new stake in MAIA Biotechnology during the first quarter valued at $71,000. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.